Primary Prevention of Alzheimer's Disease: How Far Off Is It?
MaisuZenwaveWhen we talk about Alzheimer's disease, the conversation is often dominated by sobering realities: more than 57 million people worldwide living with dementia, nearly 10 million new cases each year, and an economic burden reaching $1.3 trillion[1]. In the face of a neurodegenerative disease for which no cure exists, the focus of the medical community is quietly shifting—from care after diagnosis to interception before symptoms appear. Primary prevention, by definition, means taking action against underlying causes before any detectable impairment in cognitive function occurs, in order to stop the disease from developing. So how far is this line of defense from the average person?
The answer may be closer than we imagine—but the meaning of "close" requires careful qualification. What is close is the accumulation of scientific evidence and the formation of a public health consensus; what remains distant is the translation of population-level risk attribution into an individualized, certain promise of "not getting sick."
From the standpoint of scientific evidence, the feasibility of primary prevention has already achieved landmark confirmation. In its updated guidelines, the World Health Organization explicitly states that up to 45% of dementia risk can be attributed to modifiable factors, including smoking, heavy alcohol use, physical inactivity, social isolation, air pollution, and noncommunicable diseases such as hypertension and diabetes[2]. This figure is transformative: it means that nearly half of all potential cases are, in theory, not inevitable. Even more persuasive is the evidence from intervention trials. The Finnish FINGER study, a randomized controlled trial, delivered a two-year multidomain intervention—covering diet, exercise, cognitive training, and vascular risk monitoring—to older adults at risk of cognitive decline, and found that the intervention group used significantly fewer inpatient services and emergency department visits than the control group[3], suggesting that systematic lifestyle adjustment can not only affect cognitive function but also translate into measurable savings in medical resources. Even among those at the highest genetic risk, favorable lifestyle factors can still substantially reduce dementia risk. This shows that genes are not destiny, and that primary prevention has a real biological foothold.
Yet between the "proportion that is preventable" and an "actionable individual plan" lies a cognitive divide. Statements from authoritative bodies remain cautiously restrained. No method has yet been proven to prevent Alzheimer's disease and related dementias, and the current evidence for physical activity, blood pressure control, and cognitive training is described as "encouraging but not conclusive." Such wording does not deny the value of prevention; rather, it distinguishes epidemiological "risk reduction" from clinical "disease interception." A person who exercises regularly, controls blood pressure, and maintains social connections does indeed lower his or her statistical probability of developing dementia—but no doctor can guarantee on that basis that he or she "will not get sick." In its current form, primary prevention is more a collection of risk management measures than a vaccine-like shield.
What may truly bring primary prevention "closer" is the clarification of the intervention window. Follow-up analyses of the FINGER study found that older adults in the "pre-frail" stage were particularly sensitive to the cognitive benefits of multidomain intervention[3]. This suggests that prevention is not a matter of "the earlier the better," nor is it one-size-fits-all; rather, there is an identifiable window in which the benefits are greatest. At the same time, the modifiability of sensory function has entered the prevention landscape: hearing loss has been added to the list of risk factors, and vision correction—glasses, cataract surgery—has been estimated to be associated with the avoidance of as many as 100,000 dementia cases in the United States. These findings move primary prevention from the abstract slogan of "healthy living" to concrete, accessible, and affordable clinical actions: a blood pressure check, a hearing aid, an eye exam.
The setting where primary prevention is closest to us is not, in fact, the neurology ward, but the community health center and each person's daily decisions. It does not require waiting for the arrival of a miracle drug; it requires systematically embedding measures already known to be effective into daily life. The problem is that knowing does not equal doing. When adherence to antihypertensive medication remains poor, when sedentary behavior becomes the default, and when social isolation spreads among older adults, the "distance" of primary prevention lies not at the scientific level but at the level of implementation.
Therefore, answering "how far away" requires distinguishing between two kinds of distance. From evidence to guidelines, the distance has all but disappeared. WHO has incorporated multidomain intervention, vascular risk management, cognitive training, and social participation into its formal recommendations. From guidelines to actual behavior change in each individual, the distance remains long. Closing this distance does not depend on the next breakthrough study; it depends on whether public health systems can integrate dementia risk screening into routine chronic disease management, whether communities can offer affordable intervention programs, and whether each person is willing—at an age when nothing yet feels wrong—to make some uncomfortable choices on behalf of the self that will exist twenty years from now[4].
Primary prevention of Alzheimer's disease is not a door about to open, but a road already paved that few have chosen to walk. How far away it is from us ultimately depends on how close we are willing to walk toward it.
[1]World Health Organization. (2026). Dementia (Fact sheet).
https://www.who.int/news-room/fact-sheets/detail/dementia
[2]World Health Organization. (2026). New WHO guidelines: up to 45% of dementia risk could be prevented or delayed.
[3]Sääskilahti, M., et al. (2024). The effect of multidomain lifestyle intervention on health care service use and costs: secondary analyses from the FINGER trial. Age and Ageing, 53(11), afae249.
https://pubmed.ncbi.nlm.nih.gov/39577838/
[4]World Health Organization. (2026). Risk reduction of cognitive decline and dementia: WHO guidelines: executive summary, 2nd ed. (WHO Reference Number: B09867).
https://www.who.int/southeastasia/publications/i/item/B09867
